Figure 4 . Cytotoxicity activity of empty unmodified and modified VLPs on 4T1 breast tumor mouse cell line model, and 293T healthy embryonic kidney human cells. Two-way RM ANOVA (p<0.001). *** Significative difference between the two preparations at the same concentration. ‡ Significative difference with the control.
The same cytotoxicity experiments were performed with GOx-containing nanoreactors (Figs. 5 and 6). The results were expressed based on both GOx content and nanoreactor GOx activity. These two forms to express the treatment doses are due because the protein content of the two preparations is significantly different, and if the GOx content is similar in capsid base the enzymatic activity changes when the nanoreactor is covered with HAS (Table 1). On the 4T1 breast tumor cells, the LD50 values were 0.04 µg GOx/mL for VLP-GOx and around 0.1 µg GOx/mL for VLP-GOx@HSA, and no metabolic activity was detected at 1 µg GOx/mL for both preparations (Fig. 5a). The 4T1 tumor cells showed an LD50 at around 1 mU of GOx activity per mL of cell culture, and no metabolic activity at around 10 mU/mL in both preparations (Fig. 5b).